Pulmatrix (NASDAQ:PULM) versus Onconetix (NASDAQ:ONCO) Financial Analysis

Pulmatrix (NASDAQ:PULM) and Onconetix (NASDAQ:ONCO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Pulmatrix and Onconetix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-94.13%	-85.42%
Onconetix	-4,011.43%	-632.63%	-160.97%

Analyst Recommendations

This is a breakdown of current recommendations for Pulmatrix and Onconetix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1	0	0	0	1.00
Onconetix	1	0	0	0	1.00

Earnings and Valuation

This table compares Pulmatrix and Onconetix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81 million	N/A	-$9.56 million	($1.70)	-1.33
Onconetix	$2.52 million	0.99	-$58.69 million	$10.89	0.15

Pulmatrix has higher revenue and earnings than Onconetix. Pulmatrix is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by company insiders. Comparatively, 1.0% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Pulmatrix has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.45, indicating that its stock price is 245% more volatile than the S&P 500.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.